GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM

Detalhes bibliográficos
Autor(a) principal: Peres Alves, Rui
Data de Publicação: 2011
Outros Autores: Ramos, Fernando
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25756/rpf.v3i4.81
Resumo: The health systems are becoming broader and more complex and healthcare expenditure has never been so high, consuming an increased part of the national income, more than 10% of gross domestic product (GDP). In the last decade, medicines spending had a particular growth, having contributed decisively to the rise of total health expenditure.In order to contain medicines expenditure several policies have been introduced in Portugal. The subsidiary objectives have been the promotion of the usage of generic medicines and the introduction of market mechanisms to encourage prices reductions. But with a low rate of success so far.Although penetration is still modest, with a market share below 20%, the generic medicines have already generated significant savings in total medicines expenditure, accounted between 2003 and 2009 more than 1.7 billion Euros savings.Over the next five years the potential growth of the generic medicines market will be considerable, taking the number of products that will lose the exclusive rights to market by the end of their patents during that  period. However, to maximize these advantages, Portugal will need to undertake several measures aimed to remove existing restrictions and imperfections of generic medicines market: (i) reduce or eliminate the regulatory pressure on prices (ii) abolish the conditions that favour the practices of patent linkage, (iii) create incentives for doctors to prescribe generic medicines, (iv) implement a system for pharmacy remuneration based on pharmaceutical act fee or regressive margins, (v) create greater differentiation with regard to patients co-payment towards the option of using a more expensive branded medicine instead of a cheaper generic medicine.
id RCAP_2fc88823c863fb37619f3a0a7441dbe0
oai_identifier_str oai:ojs.farmacoterapia.pt:article/81
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEMMEDICAMENTOS GENÉRICOS E SUSTENTABILIDADE DO SNSThe health systems are becoming broader and more complex and healthcare expenditure has never been so high, consuming an increased part of the national income, more than 10% of gross domestic product (GDP). In the last decade, medicines spending had a particular growth, having contributed decisively to the rise of total health expenditure.In order to contain medicines expenditure several policies have been introduced in Portugal. The subsidiary objectives have been the promotion of the usage of generic medicines and the introduction of market mechanisms to encourage prices reductions. But with a low rate of success so far.Although penetration is still modest, with a market share below 20%, the generic medicines have already generated significant savings in total medicines expenditure, accounted between 2003 and 2009 more than 1.7 billion Euros savings.Over the next five years the potential growth of the generic medicines market will be considerable, taking the number of products that will lose the exclusive rights to market by the end of their patents during that  period. However, to maximize these advantages, Portugal will need to undertake several measures aimed to remove existing restrictions and imperfections of generic medicines market: (i) reduce or eliminate the regulatory pressure on prices (ii) abolish the conditions that favour the practices of patent linkage, (iii) create incentives for doctors to prescribe generic medicines, (iv) implement a system for pharmacy remuneration based on pharmaceutical act fee or regressive margins, (v) create greater differentiation with regard to patients co-payment towards the option of using a more expensive branded medicine instead of a cheaper generic medicine.Os sistemas de saúde são cada vez mais amplos e mais complexos, sendo que a despesa em cuidados de saúde nunca foi tão alta, consumindo uma parte cada vez maior do rendimento nacional, mais de 10 por cento do produto interno bruto (PIB). Na última década, a despesa com medicamentos teve um particular incremento, contribuindo de forma decisiva no aumento da despesa total com a saúde.Têm sido várias as políticas introduzidas em Portugal com o propósito de conter a despesa com os medicamentos. Os objectivos subsidiários têm sido a promoção da utilização dos medicamentos genéricos e a procura de mecanismos de mercado para motivar uma descida de preços, mas com um sucesso limitado. Embora a penetração seja ainda modesta, com uma quota de mercado inferior a 20 por cento, os medicamentos genéricos permitiram já gerar poupanças significativas na despesa total com os medicamentos, compreendendo uma poupança efectiva superior a € 1,7 mil milhões entre 2003 e 2009.Nos próximos cinco anos o potencial de crescimento do mercado de medicamentos genéricos é enorme, como sequência do número de produtos que vão perder os direitos de exclusividade de mercado pelo fim das respectivas patentes nesse período. Contudo, para maximizar essas vantagens, Portugal terá de empreender um conjunto de medidas que eliminem as actuais imperfeições e restrições de mercado dos medicamentos genéricos: (i) reduzir ou eliminar a pressão reguladora sobre os preços, (ii) abolir as condições que favoreçam as práticas de patent linkage, (iii) criar incentivos aos médicos para prescreverem medicamentos genéricos, (iv) implementar um sistema de remuneração da farmácia baseado no acto farmacêutico ou em margens regressivas, (v) criar uma maior diferenciação relativamente ao co-pagamento dos doentes perante a opção de usar um medicamento de marca mais caro em vez de optar por um medicamento genérico mais barato.Formifarma2011-12-25info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v3i4.81https://doi.org/10.25756/rpf.v3i4.81Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 3 No 4 (2011): Outubro; 23-34Revista Portuguesa de Farmacoterapia; v. 3 n. 4 (2011): Outubro; 23-342183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/81http://revista.farmacoterapia.pt/index.php/rpf/article/view/81/65Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessPeres Alves, RuiRamos, Fernando2023-09-01T04:33:20Zoai:ojs.farmacoterapia.pt:article/81Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:33.158336Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
MEDICAMENTOS GENÉRICOS E SUSTENTABILIDADE DO SNS
title GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
spellingShingle GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
Peres Alves, Rui
title_short GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
title_full GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
title_fullStr GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
title_full_unstemmed GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
title_sort GENERIC MEDICINES AND THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM
author Peres Alves, Rui
author_facet Peres Alves, Rui
Ramos, Fernando
author_role author
author2 Ramos, Fernando
author2_role author
dc.contributor.author.fl_str_mv Peres Alves, Rui
Ramos, Fernando
description The health systems are becoming broader and more complex and healthcare expenditure has never been so high, consuming an increased part of the national income, more than 10% of gross domestic product (GDP). In the last decade, medicines spending had a particular growth, having contributed decisively to the rise of total health expenditure.In order to contain medicines expenditure several policies have been introduced in Portugal. The subsidiary objectives have been the promotion of the usage of generic medicines and the introduction of market mechanisms to encourage prices reductions. But with a low rate of success so far.Although penetration is still modest, with a market share below 20%, the generic medicines have already generated significant savings in total medicines expenditure, accounted between 2003 and 2009 more than 1.7 billion Euros savings.Over the next five years the potential growth of the generic medicines market will be considerable, taking the number of products that will lose the exclusive rights to market by the end of their patents during that  period. However, to maximize these advantages, Portugal will need to undertake several measures aimed to remove existing restrictions and imperfections of generic medicines market: (i) reduce or eliminate the regulatory pressure on prices (ii) abolish the conditions that favour the practices of patent linkage, (iii) create incentives for doctors to prescribe generic medicines, (iv) implement a system for pharmacy remuneration based on pharmaceutical act fee or regressive margins, (v) create greater differentiation with regard to patients co-payment towards the option of using a more expensive branded medicine instead of a cheaper generic medicine.
publishDate 2011
dc.date.none.fl_str_mv 2011-12-25
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25756/rpf.v3i4.81
https://doi.org/10.25756/rpf.v3i4.81
url https://doi.org/10.25756/rpf.v3i4.81
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://revista.farmacoterapia.pt/index.php/rpf/article/view/81
http://revista.farmacoterapia.pt/index.php/rpf/article/view/81/65
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Formifarma
publisher.none.fl_str_mv Formifarma
dc.source.none.fl_str_mv Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 3 No 4 (2011): Outubro; 23-34
Revista Portuguesa de Farmacoterapia; v. 3 n. 4 (2011): Outubro; 23-34
2183-7341
1647-354X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799129986127364096